Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 43

Cited In for PubMed (Select 18201203)


A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy.

George RE, Joseph S.

Saudi Pharm J. 2014 Nov;22(5):403-10. doi: 10.1016/j.jsps.2013.05.005. Epub 2013 May 28. Review.


Observational and clinical trial findings on the comparative effectiveness of diabetes drugs showed agreement.

Flory JH, Mushlin AI.

J Clin Epidemiol. 2015 Feb;68(2):200-10. doi: 10.1016/j.jclinepi.2014.09.001. Epub 2014 Nov 26.


Risk of diarrhea in patients with type 2 diabetes mellitus treated with sitagliptin: a meta-analysis of 30 randomized clinical trials.

Zhao Q, Hong D, Zheng D, Xiao Y, Wu B.

Drug Des Devel Ther. 2014 Nov 11;8:2283-94. doi: 10.2147/DDDT.S70945. eCollection 2014.


Effect of sitagliptin on lipid profile in patients with type 2 diabetes mellitus.

Shigematsu E, Yamakawa T, Kadonosono K, Terauchi Y.

J Clin Med Res. 2014 Oct;6(5):327-35. doi: 10.14740/jocmr1889w. Epub 2014 Jul 28.


Predictive factors of durability to sitagliptin: Slower reduction of glycated hemoglobin, older age and higher baseline glycated hemoglobin.

Chung HS, Suh S, Kim MY, Kim SK, Kim HK, Lee JI, Hur KY, Kim JH, Min YK, Lee MS, Kim KW, Kim SW, Chung JH, Lee MK.

J Diabetes Investig. 2014 Feb 12;5(1):51-9. doi: 10.1111/jdi.12127. Epub 2013 Sep 2.


Challenges in achieving optimal glycemic control in type 2 diabetes patients with declining renal function: The Southeast Asia perspective.

Cc Chow F, Chan SP, Hwu CM, Suwanwalaikorn S, Wu AY, Gan SY, Zacarias MB.

J Diabetes Investig. 2012 Dec 20;3(6):481-9. doi: 10.1111/jdi.12006. Review.


Comparative evaluation of incretin-based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure.

Nauck MA, Vardarli I.

J Diabetes Investig. 2010 Apr 22;1(1-2):24-36. doi: 10.1111/j.2040-1124.2010.00004.x. Review.


Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison.

Craddy P, Palin HJ, Johnson KI.

Diabetes Ther. 2014 Jun;5(1):1-41. doi: 10.1007/s13300-014-0061-3. Epub 2014 Mar 25.


Impact of three oral antidiabetic drugs on markers of β-cell function in patients with type 2 diabetes: a meta-analysis.

Lu J, Zang J, Li H.

PLoS One. 2013 Oct 25;8(10):e76713. doi: 10.1371/journal.pone.0076713. eCollection 2013.


A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment.

Eligar VS, Bain SC.

Drug Des Devel Ther. 2013 Aug 30;7:893-903. doi: 10.2147/DDDT.S32331. eCollection 2013. Review.


Safety and efficacy of sitagliptin-metformin in fixed combination for the treatment of type 2 diabetes mellitus.

Ballav C, Gough SC.

Clin Med Insights Endocrinol Diabetes. 2013 Sep 1;6:25-37. doi: 10.4137/CMED.S7314. Review.


Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin.

Steinberg H, Anderson MS, Musliner T, Hanson ME, Engel SS.

Vasc Health Risk Manag. 2013;9:273-82. doi: 10.2147/VHRM.S44330. Epub 2013 May 29. Review.


Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies.

Engel SS, Round E, Golm GT, Kaufman KD, Goldstein BJ.

Diabetes Ther. 2013 Jun;4(1):119-45. doi: 10.1007/s13300-013-0024-0. Epub 2013 May 23.


Effect of addition of either sitagliptin or pioglitazone in patients with uncontrolled type 2 diabetes mellitus on metformin: A randomized controlled trial.

Chawla S, Kaushik N, Singh NP, Ghosh RK, Saxena A.

J Pharmacol Pharmacother. 2013 Jan;4(1):27-32. doi: 10.4103/0976-500X.107656.


The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes.

Tschöpe D, Hanefeld M, Meier JJ, Gitt AK, Halle M, Bramlage P, Schumm-Draeger PM.

Cardiovasc Diabetol. 2013 Apr 10;12:62. doi: 10.1186/1475-2840-12-62. Review.


A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus.

Gross JL, Rogers J, Polhamus D, Gillespie W, Friedrich C, Gong Y, Monz BU, Patel S, Staab A, Retlich S.

BMJ Open. 2013 Mar 5;3(3). pii: e001844. doi: 10.1136/bmjopen-2012-001844.


Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis.

Engel SS, Golm GT, Shapiro D, Davies MJ, Kaufman KD, Goldstein BJ.

Cardiovasc Diabetol. 2013 Jan 3;12:3. doi: 10.1186/1475-2840-12-3.


Effects of 6-month sitagliptin treatment on glucose and lipid metabolism, blood pressure, body weight and renal function in type 2 diabetic patients: a chart-based analysis.

Yanai H, Adachi H, Hamasaki H, Masui Y, Yoshikawa R, Moriyama S, Mishima S, Sako A.

J Clin Med Res. 2012 Aug;4(4):251-8. doi: 10.4021/jocmr975w. Epub 2012 Jul 20.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk